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Live covisualisation of competing adeno-associated virus and
herpes simplex virus type 1 DNA replication. Molecular
mechanisms of interaction
Abstract
We performed live cell visualization assays to directly assess the interaction between competing
adeno-associated virus (AAV) and herpes simplex virus type 1 (HSV-1) DNA replication. Our studies
reveal the formation of separate AAV and HSV-1 replication compartments and the inhibition of HSV-1
replication compartment formation in the presence of AAV. AAV Rep is recruited into AAV replication
compartments but not into those of HSV-1, while the single-stranded DNA-binding protein HSV-1 ICP8
is recruited into both AAV and HSV-1 replication compartments, although with differential staining
patterns. Slot blot analysis of coinfected cells revealed a dose-dependent inhibition of HSV-1 DNA
replication by wild-type AAV but not by rep-negative recombinant AAV. Consistent with this, Western
blot analysis indicated that wild-type AAV affects the levels of the HSV-1 immediate-early protein
ICP4 and the early protein ICP8 only modestly but strongly inhibits the accumulation of the late proteins
VP16 and gC. Furthermore, we demonstrate that the presence of Rep in the absence of AAV DNA
replication is sufficient for the inhibition of HSV-1. In particular, Rep68/78 proteins severely inhibit the
formation of mature HSV-1 replication compartments and lead to the accumulation of ICP8 at sites of
cellular DNA synthesis, a phenomenon previously observed in the presence of viral polymerase
inhibitors. Taken together, our results suggest that AAV and HSV-1 replicate in separate compartments
and that AAV Rep inhibits HSV-1 at the level of DNA replication.
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We performed live cell visualization assays to directly assess the interaction between competing adeno-
associated virus (AAV) and herpes simplex virus type 1 (HSV-1) DNA replication. Our studies reveal the
formation of separate AAV and HSV-1 replication compartments and the inhibition of HSV-1 replication
compartment formation in the presence of AAV. AAV Rep is recruited into AAV replication compartments but
not into those of HSV-1, while the single-stranded DNA-binding protein HSV-1 ICP8 is recruited into both AAV
and HSV-1 replication compartments, although with differential staining patterns. Slot blot analysis of
coinfected cells revealed a dose-dependent inhibition of HSV-1 DNA replication by wild-type AAV but not by
rep-negative recombinant AAV. Consistent with this, Western blot analysis indicated that wild-type AAV affects
the levels of the HSV-1 immediate-early protein ICP4 and the early protein ICP8 only modestly but strongly
inhibits the accumulation of the late proteins VP16 and gC. Furthermore, we demonstrate that the presence of
Rep in the absence of AAV DNA replication is sufficient for the inhibition of HSV-1. In particular, Rep68/78
proteins severely inhibit the formation of mature HSV-1 replication compartments and lead to the accumu-
lation of ICP8 at sites of cellular DNA synthesis, a phenomenon previously observed in the presence of viral
polymerase inhibitors. Taken together, our results suggest that AAV and HSV-1 replicate in separate com-
partments and that AAV Rep inhibits HSV-1 at the level of DNA replication.
Adeno-associated virus (AAV), a nonpathogenic human
parvovirus, is a small, nonenveloped DNA virus with a single-
stranded DNA (ssDNA) genome of 4,680 nucleotides (nt). The
AAV genome consists of two open reading frames, carrying the
rep and the cap genes, flanked by two 145-nt inverted terminal
repeats (ITRs). The rep gene encodes the nonstructural repli-
cation proteins (Rep), while the cap gene encodes the capsid
proteins forming the icosahedral capsid. AAV has a unique,
biphasic life cycle that is characterized by productive infection
in the presence of helper viruses, such as adenovirus (Ad) or a
herpesvirus, and latent infection, which occurs in the absence
of a helper virus (reviewed in reference 32). The AAV type 2
(AAV2) genome, for instance, can site-specifically integrate
into human chromosome 19 at position 19q13.4, a locus that is
termed AAVS1. In addition, AAV, and in particular rep-nega-
tive recombinant AAV (rAAV) gene delivery vectors, can also
maintain a latent infection by episomal maintenance of circu-
larized genomes (reviewed in reference 28). The AAV Rep
proteins are multifunctional regulatory proteins essential for
viral DNA replication, regulation of gene expression, site-spe-
cific integration, and packaging of viral genomes into capsids
(reviewed in reference 32). Infection of a cell with AAV has
pleiotropic, mostly inhibitory effects on both the host cell and
the helper virus. For instance, cell cycle arrest can be induced
by either AAV Rep (3, 35) or single-stranded AAV DNA (22,
33), whereas AAV Rep was demonstrated to inhibit replication
of a number of heterologous viruses (reviewed in reference
15).
Herpes simplex virus type 1 (HSV-1), on the other hand, is
a large, enveloped DNA virus and an important human patho-
gen. The HSV-1 genome consists of a 152-kb double-stranded
DNA and encodes approximately 80 gene products, which are
expressed in a temporally regulated cascade. In particular,
HSV-1 genes are classified as immediate-early (IE or ), early
(), and late () genes. The first genes to be expressed upon
infection are the IE genes, encoding several transactivator
proteins, which in turn initiate transcription of the early and
some late genes, called leaky late or 1 genes. Early gene
products comprise the viral DNA replication factors initiating
viral DNA synthesis, which in turn stimulates expression of the
leaky late (1) and true late (2) genes. The latter encode
mainly structural virion proteins. The life cycle of HSV-1 is
characterized by productive (lytic) replication in epithelial cells
of the mucosa and life-long latent infection in the correspond-
ing sensory neurons, from which HSV-1 can sporadically reac-
tivate (reviewed in reference 42). HSV-1 and HSV-2 are helper
viruses for AAV replication (4), with the helicase-primase
complex (encoded by UL5, UL8, and UL52) and the ssDNA-
binding protein ICP8 (encoded by UL29) acting as the minimal
helper factors required for productive AAV replication (50).
Notably, enzymatic function of the helicase-primase complex is
not required for the helper activity; rather, the helicase-pri-
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mase complex appears to be required for correct subnuclear
localization of ICP8, suggesting that ICP8 is the key helper
factor (36, 40).
On several occasions, AAV was suggested to cause inhibi-
tion of HSV-1 replication. In particular, coinfection with AAV
inhibited replication of HSV-1 in simian virus 40-transformed
hamster cells (1). A subsequent study reported the inhibition
of HSV-1 oriS-dependent replication by cotransfection of
AAV rep-expressing plasmids (18). More recently, we and oth-
ers demonstrated that the rep gene present in HSV/AAV hy-
brid amplicon vectors inhibited vector replication and/or pack-
aging, resulting in up to 2,000-fold reduced titers of packaged
vector stocks (20, 48). However, only a little is known about the
molecular mechanisms of AAV-mediated inhibition of HSV-1
replication.
Recent studies have addressed the interaction between
AAV and the helper virus HSV-1. In a first study, Rep was
shown to colocalize with ICP8 in AAV–HSV-1-coinfected
cells, but not when rep was expressed from a recombinant
HSV-1 in the absence of AAV DNA. The same study also
demonstrated a direct interaction of Rep with ICP8, which was
enhanced upon the addition of ssDNA (19). A second study
also showed a partial overlap of Rep with ICP8 when cells were
either coinfected with AAV and HSV-1 or cotransfected with
an AAV plasmid and the minimal HSV-1 helper factors. The
same study also confirmed the direct binding of Rep to ICP8
and, in addition, showed that this interaction enhanced Rep
binding to and nicking of the AAV ITRs (40). However, these
studies did not directly assess the relative subnuclear distribu-
tions of replicating AAV and HSV-1 DNAs.
In the present study, we directly covisualize DNA replication
of AAV and HSV-1 in live cells. The assays reveal the forma-
tion of separate AAV and HSV-1 replication compartments
(RCs), with recruitment of Rep into AAV but not into HSV-1
RCs. HSV-1 ICP8 accumulates at both AAV and HSV-1 RCs,
although with differential staining patterns. However, the for-
mation of HSV-1 RCs is markedly inhibited in the presence of
AAV. Consistent with this, we show that replication of HSV-1
is inhibited by coinfection with wild-type (wt) AAV2, but not
with a rep-negative rAAV, and that this inhibition occurs at the
level of HSV-1 DNA replication while only modestly affecting
HSV-1 IE and early gene expression. Finally, we demonstrate
that the mere presence of AAV Rep proteins in the absence of
AAV DNA replication is sufficient for inhibition of HSV-1. In
particular, Rep68/78 proteins severely inhibit the formation of
mature HSV-1 RCs and lead to the accumulation of ICP8 at
sites of cellular DNA synthesis, a phenomenon observed pre-
viously in the presence of viral polymerase inhibitors (27, 47).
MATERIALS AND METHODS
Cells and viruses. (i) Cells. HeLa, Vero, and Vero 2-2 cells (37) were main-
tained in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 100 units/ml penicillin G, 100 g/ml streptomycin, and
0.25 g/ml amphotericin B. For culture of Vero 2-2 cells, 500 g/ml G418 was
included in the medium.
(ii) HSV-1. HSV-1 strain F was grown and titrated in Vero 2-2 cells. The
recombinant HSV-1 viruses vECFP-ICP4 and vEYFP-ICP4, expressing en-
hanced cyan fluorescent protein (ECFP) and enhanced yellow fluorescent pro-
tein (EYFP) fused to the N terminus of ICP4 from the native IE3 promoter (11),
were kindly provided by R. D. Everett (MRC Virology Unit, Glasgow, United
Kingdom).
(iii) AAV. wt AAV2 and rAAV2-GFP were produced by using the two-plasmid
protocol described by Zolotukhin and colleagues (54), with the following mod-
ifications. 293T cells (ATCC) were grown in triple flasks for 24 h (DMEM plus
10% FBS) prior to adding the calcium phosphate precipitate. rAAV2-GFP was
generated using plasmids pTRUF11 (obtained from S. Zolotukhin, University of
Florida, FL) and pDG (17), while wt AAV2 was generated using pAV2 (24)
instead of pTRUF11. After 72 h, the virus was purified from Benzonase-treated
crude cell lysates over an iodixanol density gradient (Optiprep; Greiner Bio-
One), followed by heparin-agarose type I affinity chromatography (Sigma). Fi-
nally, viruses were concentrated and formulated in lactated Ringer’s solution
(Baxter), using Vivaspin 20 50,000-molecular-weight-cutoff centrifugal concen-
trators (Vivascience), and then stored at 80°C. The biochemical purity of the
virus stocks (95%) was assessed by silver staining after electrophoresis. rAAV2
transducing unit (TU) titers were determined as follows: C12 cells (6) were
coinfected with serial dilutions of rAAV-GFP vector stocks and wt Ad5 (multi-
plicity of infection [MOI] of 20), followed by fluorescence-activated cell sorting
analysis after 42 h. wt AAV2 infectious unit (IU) titers were determined on HeLa
cells coinfected with wt Ad (MOI, 20). After 42 h, cells were transferred to nylon
membranes (Millipore), followed by hybridization using a 32P-radiolabeled
AAV2 rep probe.
Antibodies. (i) Primary antibodies. The anti-HSV-1 ICP8 monoclonal anti-
body (MAb) 7381 was kindly provided by R. D. Everett (MRC Virology Unit,
Glasgow, United Kingdom). The rabbit anti-HSV-1 ICP8 serum 4-83 (23) was a
kind gift of D. M. Knipe (Harvard Medical School, Boston, MA). Anti-HSV-1
VP16 MAb LP1 (29) was kindly donated by A. Minson and H. Browne (Uni-
versity of Cambridge, Cambridge, United Kingdom). Rabbit anti-HSV-1 gC
serum R47 (7) was a kind gift of G. H. Cohen and R. J. Eisenberg (University of
Pennsylvania, Philadelphia, PA). A rabbit anti-AAV Rep serum (45) was kindly
provided by J. P. Trempe (Medical University of Ohio, Toledo, OH). Anti-
HSV-1 ICP8 MAb (clone 10A3) was purchased from Abcam, anti-HSV-1 ICP4
MAb was purchased from Advanced Biotechnologies, anti-AAV Rep MAb
(clone 303.9) was purchased from Fitzgerald Industries International, anti-green
fluorescent protein (anti-GFP) MAb (JL-8) was purchased from Clontech, anti-
bromodeoxyuridine (anti-BrdU) MAb (clone BMC 9318) was purchased from
Roche, and rabbit anti-actin polyclonal antibody (H300) was purchased from
Santa Cruz Biotechnology.
(ii) Secondary antibodies. Goat anti-rabbit immunoglobulin G heavy plus light
chains [IgG(HL)]–fluorescein isothiocyanate (FITC) and goat anti-rabbit
IgG(HL)–horseradish peroxidase were purchased from Southern Biotech, goat
anti-mouse IgG(HL)–Alexa Fluor 594 (AF594) was purchased from Molecular
Probes, and rabbit anti-mouse IgG (whole molecule)–peroxidase was purchased
from Sigma.
Plasmids. Plasmids pRep, pR68/78, pEYFPTetR, pECFPTetR, pBstetO, and
pAAVlacO were described previously (13, 16, 20). Plasmid pSV2-EYFP/lacI,
expressing a fusion gene for EYFP linked to the lac repressor (LacI) (46), was
kindly provided by D. L. Spector (Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY). Plasmid pALZ14ECFP-NHPX, encoding the nucleolar NHPX pro-
tein fused to ECFP under the control of the human cytomegalovirus IE1 en-
hancer/promoter (CMV promoter) (25), was kindly provided by A. I. Lamond
(University of Dundee, Dundee, Scotland, United Kingdom). The standard
HSV-1 amplicon plasmid pHSVPrPUC was kindly provided by H. J. Federoff
(University of Rochester School of Medicine and Dentistry, Rochester, NY).
Plasmid p5CR, encoding mCherry fused to the N terminus of AAV Rep68/78
from the p5 promoter as well as unmodified Rep52/40 from the p19 promoter,
was kindly provided by A. Salvetti (INSERM U758—ENSL, Lyon, France).
Plasmid pCMV-8GFP, expressing GFP fused to the C terminus of HSV-1 ICP8
from the CMV promoter (43), was kindly provided by D. M. Knipe (Harvard
Medical School, Boston, MA). Plasmid pcDNA-mRFP1-N, containing the gene
for monomeric red fluorescent protein (mRFP) under the control of the CMV
promoter, was kindly provided by U. F. Greber (Institute of Zoology, University
of Zurich, Zurich, Switzerland).
Construction of the other plasmids used in this study was done as follows. (i)
For pHSV-tetO (an HSV-1 amplicon plasmid containing tetracycline operator
[teto] sequences), a 1.65-kb HindIII-KpnI fragment of pBstetO (containing the
teto sequences) (16) was inserted between the HindIII and KpnI sites of
pHSVPrPUC, resulting in plasmid pHSV-tetO. pHSV-tetO contains a total of 35
TetR-binding sites. (ii) For plasmid pCMVUL29-mRFP (expressing mRFP
fused to the C terminus of HSV-1 ICP8 from the CMV promoter), a 4.5-kb
SpeI-SalI fragment of plasmid pCMV-8GFP (containing the UL29 open reading
frame [ORF] and the C-terminal 688 bp of the CMV promoter) was inserted
between the SpeI and SalI sites of the pBluescript SK() cloning vector (Strat-
agene), resulting in plasmid pCMVUL29. A 4.53-kb SpeI-KpnI fragment of
pCMVUL29 (containing the UL29 ORF and the C-terminal 688 nt of the CMV
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promoter) was then inserted between the SpeI and KpnI sites of pcDNA-
mRFP1-N (containing the N-terminal 152 nt of the CMV promoter and the
mRFP ORF), resulting in pCMVUL29-mRFP. (iii) For plasmid pCMVmRF-
PLacI (expressing an mRFP-LacI fusion including a nuclear localization signal
[NLS] from the CMV promoter), the ORF for mRFP without the stop codon was
PCR amplified with primers containing a HindIII site at the 5 end and an EcoRI
site at the 3 end, using plasmid pcDNA-mRFP1-N as the template. The result-
ing PCR product was inserted between the HindIII and EcoRI sites of pBlue-
script SK(), resulting in plasmid pBsmRFP. Likewise, the ORF encoding LacI
including an NLS was PCR amplified with primers containing an EcoRI site at
the 5 end and a NotI site at the 3 end, using plasmid pSV2-EYFP/lacI as the
template. The resulting PCR product was then ligated between the EcoRI and
NotI sites on plasmid pBsmRFP, resulting in plasmid pBsmRFPLacI. Finally, a
1.8-kb HindIII-NotI fragment of pBsmRFPLacI (containing the mRFP-LacI
fusion gene including an NLS) was inserted between the HindIII and NotI
sites of pcDNA-mRFP1-N, resulting in pCMVmRFPLacI. (iv) For plasmid
pCMVrep68/78_AL (encoding AAV2 Rep68/78 under the control of the CMV
promoter), the ORF encoding AAV2 Rep68/78 was PCR amplified with primers
introducing a BglII site at the 5 end and a NotI site at the 3 end, using plasmid
pR68/78 as the template. The resulting PCR product was ligated between the
BglII and NotI sites of pEGFP-N3 (Clontech), resulting in plasmid pCMVrep68/
78_AL. The sequence of the rep68/78 ORF was confirmed by sequencing. (v)
pCMVrep-ECFP-N3 (expressing the first 522 codons of rep68/78 fused to ECFP
from the CMV promoter) was constructed in two steps. First, pECFP (Clontech)
was cut with PinAI and XmaI and religated, resulting in pECFP-N3, with a
shifted ORF for ECFP. Subsequently, a 0.74-kb BamHI-NotI fragment of
pECFP-N3 (containing the gene for ECFP) was ligated with the 4.0-kb BamHI-
NotI fragment of pEGFP-N3 (containing the vector backbone and the CMV
promoter), resulting in pCMVECFP-N3. Second, a 1.62-kb BglII-KpnI fragment
of pCMVrep-EGFP (containing the first 522 codons of rep68/78) (C. Fraefel,
unpublished material) was inserted between the BglII and KpnI sites of
pCMVECFP-N3, resulting in pCMVrep-ECFP-N3.
Transfection. (i) Live visualization assays. The detailed procedure for live
visualization assays was described previously (13). Briefly, the day before trans-
fection, Vero or HeLa cells were seeded on either Lab-Tek four-well chambered
cover glasses (Nalge Nunc International), for live cell microscopy, or round
12-mm cover glasses in 24-well plates, for subsequent immunofluorescence stain-
ing, at 105 cells/well. Cells were transfected using Lipofectamine Plus reagent as
described by the manufacturer (Invitrogen). The amounts of individual plasmids
used for transfection were as follows: pHSV-tetO, pAAVlacO, pBstetO, and
pHSVPrPUC, 25 ng; and pEYFPTetR, pECFPTetR, pCMVmRFPLacI, pSV2-
EYFP/lacI, pCMVUL29-mRFP, pALZ14ECFP-NHPX, pRep, and p5CR, 10 ng.
Helper functions for HSV-1 amplicon and rAAV replication were provided by
infection with wt HSV-1, vECFP-ICP4, or vEYFP-ICP4, as indicated in the text.
For visualization of the nuclei in live cells, Hoechst 33342 (Invitrogen) was added
to the culture medium 30 min before observation, at a concentration of 1 g/ml.
(ii) Transfection-infection experiments presented in Fig. 7 and 8. Vero cells
were transfected as described for the live visualization assays, except that 20 ng
of pCMVrep68/78_AL, pEGFP-N3, or pCMVrep-ECFP-N3 was used. On the
following day, the cells were infected with HSV-1 at an MOI of 10 PFU and fixed
at the indicated time points.
Immunofluorescence. Cells were washed once with cold phosphate-buffered
saline, pH 7.4 (PBS), and fixed with 3.7% formaldehyde in PBS for 15 min at
room temperature (RT), and the fixation was stopped with 0.1 M glycine in PBS
for 5 min at RT. After being washed with cold PBS, cells were permeabilized with
acetone for 2 min at 20°C and washed again three times with cold PBS. For
detection of BrdU-labeled DNA, the cells were treated with 4 M HCl for 10 min
at RT and washed three times with PBS. The cells were then blocked with PBS-B
(PBS supplemented with 3% bovine serum albumin) for 15 min at RT and
washed once with PBS. Cells were incubated with antibodies diluted in PBS-B for
1 h at RT and washed three times with PBS between incubations with primary
and secondary antibodies. Primary antibodies were used at the following dilu-
tions: anti-HSV-1 ICP8 MAb 7381, 1:1,000; anti-HSV-1 ICP4 MAb, 1:200; rabbit
anti-AAV Rep serum, 1:400; rabbit anti-HSV-1 ICP8 serum 4-83, 1:250; and
anti-BrdU MAb clone BMC 9318, 1:20 (5 g/ml). Secondary antibodies were
used at the following dilutions: goat anti-rabbit IgG(HL)–FITC, 1:100; and
goat anti-mouse IgG(HL)–AF594, 1:100 to 1:500. For visualization of the
nuclei, the cells were incubated with 1 g/ml DAPI (4,6-diamidino-2-phenylin-
dole; Roche) in PBS for 15 min at RT. Finally, the cells were washed three times
with PBS and once with water and then mounted in Glycergel (DakoCytoma-
tion) containing 25 mg/ml DABCO (1, 4-diazabicyclo [2.2.2] octane; Fluka) to
retard bleaching.
Microscopy. Live or fixed cells were observed by confocal laser scanning
microscopy (CLSM) on a Leica TCS SP2 AOBS microscope or by epifluores-
cence microscopy on a Zeiss Axiovert S100 microscope equipped with a
Hamamatsu C5810 3CCD chilled color camera. Images from CLSM were de-
convolved with a blind deconvolution algorithm, using Huygens Essential 2.6.0p1
software (SVI), and processed with Imaris 5.0.1 (Bitplane AG) and Adobe
Photoshop Elements 2.0 software (Adobe).
Slot blotting. The day before infection, HeLa cells were plated in 24-well
plates at 2 	 105 cells/well. The cells were mock infected, infected with HSV-1
at an MOI of 1 PFU, or coinfected with HSV-1 (MOI, 1 PFU) and wt AAV2
(MOI, 10, 100, or 1,000 IU) or rAAV2-GFP (MOI, 10, 100, or 1,000 TU) in
DMEM. After 2 h of absorption, the cells were washed with PBS and covered
with DMEM containing 2% FBS. At 48 h postinfection (p.i.), the cells were
harvested and lysed in 1 ml lysis buffer (0.4 M NaOH, 10 mM EDTA) and then
boiled for 10 min. The lysate was further diluted 1:10 in lysis buffer, and 300 l
thereof (6 	 103 cell equivalents) was spotted onto a positively charged nylon
membrane (Roche), using a Bio-Dot SF microfiltration apparatus (Bio-Rad)
according to the manufacturer’s manual. HSV-1 DNA was detected with a
digoxigenin (DIG)-labeled probe for the entire HSV-1 UL35 ORF, which was
PCR amplified with primers UL35-5Ngo (5TTGAGGCCGGCGCAATTTCA
CCGCCCCAGCACCG3) and UL35-3Not/Spe (5AAAGAGCGGCCGCACT
AGTGGTGTGGTCTTTTATTGATTAAAACACCCCAG3) from a cloned
HSV-1 strain F genome (YE102 bacterial artificial chromosome) (41), using a
PCR DIG probe synthesis kit (Roche) according to the manufacturer’s manual.
Hybridization with the DIG-labeled probe and immunological detection were
performed as previously described (13, 20), except that DIG Easy Hyb (Roche)
was used as hybridization buffer. Scanned blots were quantified using Quantity
One 4.6.1 software (Bio-Rad).
Western blotting. The day before infection, HeLa cells were plated in 12-well
plates at 4 	 105 cells/well. Infections were carried out as described for the slot
blot analysis. At 48 h p.i., the cells were washed with PBS, lysed in 200 l protein
loading buffer (containing 62 mM Tris base, 2% sodium dodecyl sulfate [SDS],
5% 2-mercaptoethanol, 10% glycerol, and 0.005% bromphenol blue), and boiled
for 10 min. Twenty-microliter aliquots of the lysates (4 	 104 cell equivalents)
were separated in SDS–8% (for detection of ICP4 and ICP8) or 10% (for
detection of VP16, gC, Rep, and GFP) polyacrylamide gels and transferred to
Protran nitrocellulose membranes (Whatman). The membranes were blocked
with PBS-T (PBS containing 0.3% Tween 20) supplemented with 5% nonfat dry
milk for 1 h at RT. Incubation with antibodies was carried out in PBS-T sup-
plemented with 2.5% dry milk. Primary antibodies were incubated overnight at
4°C, while secondary antibodies were incubated for 1 h at RT. The primary
antibodies were used at the following dilutions: anti-HSV-1 ICP4 MAb, 1:10,000;
anti-HSV-1 ICP8 MAb clone 10A3, 1:10,000; anti-HSV-1 VP16 MAb LP1,
1:4,000; rabbit anti-HSV-1 gC serum R47, 1:50,000; anti-AAV Rep MAb clone
303.9, 1:200; anti-GFP MAb JL-8, 1:2,000; and rabbit anti-actin polyclonal an-
tibody H300, 1:1,000. The secondary antibodies were used as follows: rabbit
anti-mouse IgG (whole molecule)–peroxidase, 1:10,000 (for detection of ICP4,
ICP8, Rep, and GFP) or 1:100,000 (for detection of VP16); and goat anti-rabbit
IgG(HL)–horseradish peroxidase, 1:10,000. Membranes were washed three
times with PBS-T after each incubation step. Membranes were stripped with
Restore Western blot stripping buffer (Pierce) for 20 min at 37°C before being
reprobed with a different primary antibody. Bound secondary antibodies were
detected with ECL Western blotting detection reagent (Amersham Biosciences),
and the membranes were exposed to Lumi-Film chemiluminescence detection
films (Roche). Scanned blots were quantified using Quantity One 4.6.1 software
(Bio-Rad).
RESULTS
Live covisualization of AAV and HSV-1 DNA replication. In
order to directly assess the reciprocal interaction between
AAV and HSV-1 on the single-cell level, we set out to visualize
the replication of an rAAV genome and an HSV-1 amplicon
plasmid in live cells. For visualization of rAAV DNA replica-
tion, we used a previously described visualization system em-
ploying the interaction of the lac repressor (LacI) fused to
autofluorescent proteins with lac operator sequences (LacO)
present in an rAAV genome (rAAVlacO) (13). An EYFP-LacI
fusion was expressed from plasmid pSV2-EYFP/lacI (46),
while an mRFP-LacI fusion was expressed from plasmid
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pCMVmRFPLacI. For the visualization of HSV-1 amplicon
replication, we employed the interaction of tetracycline oper-
ator (TetO) sequences present within an HSV-1 amplicon plas-
mid (pHSV-tetO) with the tetracycline repressor (TetR)
DNA-binding domain fused to autofluorescent proteins. The
TetR DNA-binding domain fused to EYFP or ECFP was ex-
pressed from plasmid pEYFPTetR or pECFPTetR, as de-
scribed previously (16). The HSV-1 helper factors for rAAVlacO
and pHSV-tetO replication were provided by infection with
HSV-1, while the AAV Rep proteins were provided by co-
transfection of plasmids expressing AAV rep from its native
promoters (plasmid pRep or p5CR). A schematic representa-
tion of the covisualization system is shown in Fig. 1.
In a first step, we tested the functionality of our visualization
system for HSV-1 amplicon replication. For this step, Vero
cells were cotransfected with plasmids pEYFPTetR and
pHSV-tetO or with control plasmids lacking either the HSV-1
oriS (pBstetO) or the TetO sequences (pHSVPrPUC) and
then infected with the recombinant HSV-1 vECFP-ICP4 ex-
pressing ECFP fused to the N terminus of ICP4 (11) or mock
infected. The formation of HSV-1 amplicon RCs recruiting
EYFP-TetR was observed only in cells cotransfected with
pHSV-tetO and pEYFPTetR and infected with HSV-1 (Fig.
2A). Notably, the ECFP-ICP4 fusion protein was recruited to
both the HSV-1 helper virus RCs and the HSV-1 amplicon
RCs, although with a lower affinity for the latter. Similarly, an
ICP8-mRFP fusion protein was localized to both the helper
virus and the HSV-1 amplicon RCs in the characteristic punc-
tate staining pattern (data not shown). Consistent with previ-
ous reports, HSV-1 amplicon and HSV-1 helper virus RCs
were clearly distinguishable and did not merge (10, 38). How-
ever, in the absence of pHSV-tetO RC formation, nonspecific
small nuclear foci of EYFP-TetR were observed. Cotransfec-
tion of a plasmid encoding the nucleolar NHPX protein fused
to ECFP (25) revealed that these small foci were invariably
localized to the nucleoli (Fig. 2B). Notably, the small nonspe-
cific foci disappeared upon the addition of tetracycline to the
culture medium, indicating that the binding of EYFP-TetR to
the nucleolus is mediated by the TetR DNA-binding domain
FIG. 1. Schematic representation of live covisualization of compet-
ing viral replication origins. Replication of an HSV-1 amplicon vector
is visualized with plasmid pHSV-tetO, which contains the HSV-1 oriS,
the HSV-1 DNA packaging/cleavage signal (pac), and five reiterations
of the seven-copy teto sequence, comprising a total of 35 TetR binding
sites. In the presence of HSV-1 replication factors, the accumulation of
concatemeric HSV-1 amplicon replication products (HSV Cc.) is vi-
sualized by binding of an EYFP-TetR or ECFP-TetR fusion protein.
Visualization of rAAV replication, which employs interactions of an
mRFP-LacI or EYFP-LacI fusion protein with laco repeats present in
an rAAV genome (rAAVlacO), has been described previously (13).
Double-stranded monomeric (AAV ITRm) and dimeric (AAV ITRd)
rAAV replication intermediates are indicated.
FIG. 2. Live covisualization of HSV-1 amplicon replication and
HSV-1 ICP4. (A) Nuclear distribution of EYFP-TetR and ECFP-
ICP4. Vero cells were cotransfected with pHSV-tetO (a to f), pBstetO
(g to i), or pHSVPrPUC (k to m) and pEYFPTetR (a to m). On the
following day, the cells were infected with recombinant HSV-1 ex-
pressing ECFP fused to ICP4 (vECFP-ICP4) at an MOI of 5 PFU (a
to c and g to m) or were mock infected (d to f). Live cells were
observed by CLSM at 12 to 16 h p.i., with settings specific for EYFP
(EYFP-TetR fusion protein) and ECFP (ECFP-ICP4 fusion protein).
The images represent projections through three-dimensional recon-
structions of the nuclei. (B) Nuclear distribution of EYFP-TetR and
the nucleolus marker ECFP-NHPX. Vero cells were cotransfected
with pEYFPTetR and pALZ14ECFP-NHPX. On the following day, live
cells were observed as described for panel A, using settings specific for
EYFP (EYFP-TetR fusion protein) and ECFP (ECFP-NHPX fusion
protein).
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(data not shown). Nevertheless, the small nonspecific EYFP-
TetR foci could readily be distinguished from large, mature
pHSV-tetO RCs. Interestingly, such nonspecific EYFP/ECFP-
TetR foci were not observed in a previous study by Sourvinos
and Everett, in which a similar live visualization system for
HSV-1 DNA was employed to study the association of parental
HSV-1 genomes with ND10 and the dynamics of HSV-1 RC
formation (38). In this previous study, the fusion proteins were
expressed by transduction of cells with an HSV-1 amplicon
vector instead of transfection (38). Possibly, in our study, the
FIG. 3. Live covisualization of HSV-1 amplicon and rAAV DNA replication. (A) Independent formation of HSV-1 amplicon and rAAV RCs.
HeLa cells were cotransfected with pHSV-tetO, pAAVlacO, pEYFPTetR, pCMVmRFPLacI, and pRep. On the following day, the cells were
infected with HSV-1 at an MOI of 5 PFU. Live cells treated with 1 g/ml Hoechst 33342 were observed by CLSM at 12 to 16 h p.i., with settings
specific for EYFP (pHSV-tetO RCs), mRFP (rAAVlacO RCs), and Hoechst. The images represent single z stacks of the nuclei. (B) Formation
of HSV-1 amplicon and rAAV RCs and nuclear distribution of AAV Rep. HeLa cells were cotransfected with pHSV-tetO, pAAVlacO,
pECFP-TetR, pSV2-EYFP/lacI, and p5CR. On the following day, the cells were infected with HSV-1 at an MOI of 1 PFU. Live cells were observed
by CLSM at 48 to 72 h p.i., with settings specific for ECFP (pHSV-tetO RCs), EYFP (rAAVlacO RCs), and mCherry (mCherry-Rep68/78 fusion
proteins). The images represent projections through three-dimensional reconstructions of the nuclei. (C) Three-dimensional views of the nucleus
shown in panel B. pHSV-tetO RCs are stained blue, rAAVlacO RCs are stained green, and mCherry-Rep68/78 proteins are stained red.
Deconvolved three-dimensional reconstructions of the nucleus were processed in Imaris software, using the surpass view mode.
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high expression levels of EYFP/ECFP-TetR 1 day after trans-
fection allowed for the formation of nonspecific foci, while in
the study of Sourvinos and Everett, the cells were observed in
the first hours after transduction, a period probably too short
for formation of such nonspecific foci (38). Taken together,
these data demonstrate the functionality of our live visualiza-
tion system for HSV-1 amplicon replication and, at the same
time, show that the observed RCs behave similar to the HSV-1
helper virus RCs with regard to size and ICP8 staining pattern,
while recruiting smaller amounts of ICP4 than the HSV-1
helper virus RCs.
In a second step, we combined the visualization systems for
HSV-1 amplicon and rAAV DNA replication. For this pur-
pose, pHSV-tetO RCs were detected with EYFP-TetR, and
rAAVlacO RCs were detected with mRFP-LacI. While the
majority of cells that displayed mature rAAV RCs did not
contain any HSV-1 amplicon RCs, a subset of cells displayed
the simultaneous formation of mature rAAV and mature
HSV-1 amplicon RCs. In these cells, the rAAV RCs formed
separately from the HSV-1 amplicon RCs. However, it ap-
peared that they were often localized in close proximity, prob-
ably reflecting the shared requirement for HSV-1 helper fac-
tors (Fig. 3A). In the next experiment, we aimed to analyze the
distribution of AAV Rep proteins in relation to rAAV and
HSV-1 amplicon RCs. For this experiment, pHSV-tetO RCs
were detected with ECFP-TetR and rAAVlacO RCs were de-
tected with EYFP-LacI, while the large Rep proteins were
expressed with mCherry fused to their N termini. While Rep
proteins were strongly recruited into the rAAV compartments,
no such accumulation was observed in HSV-1 amplicon com-
partments (Fig. 3B and C). These findings are consistent with
the presence of strong Rep-binding sites in the rAAV ITRs,
but not in the HSV-1 amplicon plasmid, and underscore the
formation of distinct rAAV and HSV-1 amplicon RCs.
The relatively infrequent coexistence of rAAV and HSV-1
amplicon RCs suggested that HSV-1 amplicon replication is
inhibited in the presence of AAV DNA replication. In order to
test this possibility, we quantified the proportion of transfected
HeLa cells positive for mature HSV-1 amplicon RCs in the
presence or absence of rAAV replication (i.e., rAAV DNA
and AAV Rep proteins). Again, HSV-1 helper factors were
provided by infection with HSV-1. Indeed, while 30% 
 2.4%
of the cells transfected with pHSV-tetO and pEYFPTetR
alone were positive for HSV-1 amplicon RCs, this proportion
was reduced to 5.7%
 1.5% in cells cotransfected with pHSV-
tetO, pEYFPTetR, pAAVlacO, and the rep-expressing plas-
mid p5CR.
HSV-1 ICP8, but not ICP4, is recruited into rAAV RCs.
HSV-1 ICP8 is an essential replication factor for both HSV-1
and AAV DNA replication (50, 53) and nonspecifically binds
ssDNA, as demonstrated by the fact that it is found not only in
HSV-1 RCs but also in AAV RCs and even at sites of cellular
DNA synthesis (9, 19, 27, 40, 47). The HSV-1 transcriptional
regulatory protein ICP4, on the other hand, displays sequence-
specific DNA-binding activity, with binding sites located
throughout the HSV-1 genome (2, 12, 30, 31). Consistent with
this, ICP4 binds to both parental HSV-1 genomes and progeny
virus DNA (11, 23, 34). In order to analyze the distribution of
ICP8 with respect to rAAV replication, rAAVlacO RCs were
detected with EYFP-LacI, while ICP8 was detected either by
antibody staining (Fig. 4A) or by expression of an ICP8-mRFP
fusion protein (Fig. 4B). While in some cells ICP8 was local-
ized almost exclusively to rAAV RCs (Fig. 4A, panels a to d),
in other cells we observed binding of ICP8 to the rAAV DNA
as well as to compartments outside the rAAV RCs, probably
representing RCs of the HSV-1 helper virus or of the rep-
expressing plasmid pRep (Fig. 4A, panels e to h, and B, panels
a to d). Plasmid pRep contains the p5 origin of DNA replica-
tion (p5 ori) and has previously been shown to replicate effi-
ciently in the presence of HSV-1 helper functions (16). Note
that the staining pattern of ICP8 within the rAAV compart-
ments was more homogenous than the punctate pattern ob-
served within the HSV-1 or pRep RCs, again underlining the
differential nature of AAV ITR, AAV p5, and HSV-1 RCs. We
next analyzed the distribution of ICP4, either by antibody
staining (Fig. 4C) or with an EYFP-ICP4 fusion protein ex-
pressed by the recombinant HSV-1 vEYFP-ICP4 (11) (Fig.
4D). In cells displaying mature rAAV RCs, ICP4 showed a
diffuse distribution within the nucleus (Fig. 4C, panels a to d)
or else was recruited into HSV-1 helper virus RCs distinct
from the rAAV RCs (Fig. 4C, panels e to h, and D, panels a to
d). Taken together, these results confirm the formation of
separate AAV and HSV-1 RCs observed with the live covisu-
alization assays shown in Fig. 3.
wt AAV2, but not a rep-negative rAAV2, inhibits HSV-1 DNA
replication. In order to find out if the observed inhibition of
HSV-1 amplicon replication in the presence of rAAV DNA
and AAV rep also holds true for the respective wt viruses, we
set out to analyze the influence of AAV2 coinfection on HSV-1
DNA replication. For this purpose, HeLa cells were infected
with HSV-1 and coinfected with increasing amounts of wt
AAV2 or a rep-negative, replication-deficient rAAV2-GFP
vector. Notably, at 48 h p.i., HSV-1-induced cytopathic effects
were visible and comparable in all cultures, either infected with
HSV-1 alone or coinfected with HSV-1 and either wt AAV2 or
rAAV-GFP (data not shown). The cells were then lysed and
the DNA analyzed by slot blot hybridization with a probe
specific for HSV-1 UL35. Clearly, wt AAV2, but not the rep-
negative rAAV2-GFP, inhibited HSV-1 DNA replication in a
dose-dependent manner (Fig. 5). The respective bands were
quantified by densitometry, with threefold serial dilutions of
HSV-1 replication products in the absence of AAV2 coinfec-
tion serving as the standard curve. The amount of HSV-1
replication products in the absence of AAV2 coinfection was
set as 100%. The results from the quantification are summa-
rized in Table 1. At the highest dose of wt AAV2 used (1,000
IU), the amount of replicated HSV-1 DNA was reduced to
approximately 23%, while even the highest dose of rAAV2-
GFP (1,000 TU) did not inhibit HSV-1 DNA replication. In
contrast, the presence of replication-defective rAAV genomes
appeared to have a slightly stimulatory, rather than inhibitory,
effect on HSV-1 DNA replication, as judged by band-intensity
readings over 100%. In summary, these results demonstrate a
dose-dependent inhibition of HSV-1 DNA replication by wt
AAV2 but not by the rep-negative, replication-defective
rAAV2-GFP. The data further indicate that although coinfec-
tion with wt AAV2 inhibits HSV-1 DNA replication, it does
not inhibit or delay the HSV-1-induced cytopathic effects.
wt AAV2 coinfection inhibits HSV-1 late gene expression.
We then proceeded to analyze the influence of AAV2 coin-
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FIG. 4. rAAV DNA replication and nuclear distribution of HSV-1 ICP8 and ICP4. (A) Covisualization of rAAV DNA and ICP8 protein. Vero cells
were cotransfected with pAAVlacO, pSV2-EYFP/lacI, and pRep. On the following day, the cells were infected with HSV-1 at an MOI of 5 PFU. At 14 h
p.i., the cells were fixed and stained with anti-ICP8 MAb 7381 and an AF594-conjugated secondary antibody, as well as DAPI. The cells were then
observed by CLSM, with settings specific for EYFP (rAAVlacO RCs), AF594 (ICP8), and DAPI. Images represent single z stacks of the nuclei. (B) Live
covisualization of rAAV DNA and ICP8. Vero cells were cotransfected with pAAVlacO, pSV2-EYFP/lacI, pCMVUL29-mRFP, and pRep. On the
following day, the cells were infected with HSV-1 at an MOI of 5 PFU. Live cells treated with 1 g/ml Hoechst 33342 were observed by CLSM at 12 to
16 h p.i., with settings specific for EYFP (rAAVlacO RCs), mRFP (ICP8-mRFP fusion protein), and Hoechst. Images represent a single z stack of a
nucleus. (C) Covisualization of rAAV DNA and ICP4. Vero cells were transfected, infected, stained, and observed as described for panel A, except that
a MAb specific for ICP4 was used. (D) Live covisualization of rAAV DNA and ICP4. Vero cells were cotransfected with pAAVlacO, pCMVmRFPLacI,
and pRep. On the following day, the cells were infected with recombinant HSV-1 expressing EYFP fused to ICP4 (vEYFP-ICP4) at an MOI of 5 PFU.
Live cells were observed as described for panel B, with settings specific for mRFP (rAAVlacO RCs), EYFP (EYFP-ICP4 fusion protein), and Hoechst.
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fection on HSV-1 protein expression. The facts that (i) AAV
does not inhibit the cytopathic effects caused by HSV-1 infec-
tion (data not shown), which can be mediated by IE gene
products (8, 21), and (ii) the HSV-1 helper factors that are
essential for AAV replication (in particular UL5, UL8, UL52,
and UL29) are all expressed with early kinetics (49, 50) led us
to the hypothesis that AAV-mediated inhibition may occur at
a late stage of HSV-1 replication without affecting IE and early
gene expression. In order to examine this possibility, we per-
formed coinfection experiments with HSV-1 and either wt
AAV2 or rAAV2-GFP, as described for Fig. 5. At 48 h p.i., the
cells were lysed and used for SDS-polyacrylamide gel electro-
phoresis and Western blotting. We used antibodies for detec-
tion of four HSV-1 proteins, in particular (i) ICP4, expressed
with IE kinetics; (ii) ICP8, expressed with early kinetics; (iii),
the IE transactivator protein VP16, expressed with leaky late
(1) kinetics; and (iv) the envelope glycoprotein C (gC), ex-
pressed with true late (2) kinetics (Fig. 6). While the levels of
ICP4 and ICP8 were moderately reduced by wt AAV2 coin-
fection, the accumulation of VP16 and gC was strongly inhib-
ited (Fig. 6A). In particular, at the highest dose of wt AAV2,
the relative signal intensities were reduced to 66% for ICP4,
47% for ICP8, 0% for VP16, and 13% for gC. In contrast,
coinfection with the rep-negative rAAV2-GFP appeared to
have a slightly stimulatory effect on ICP4, ICP8, and VP16
levels, while modestly lowering the gC level (Fig. 6A). The
blots were also probed with antibodies against AAV Rep and
GFP in order to control for efficient infection of cells by wt
AAV2 and rAAV2-GFP. As shown in Fig. 6B, infection with
increasing doses of wt AAV2 or rAAV2-GFP led to increasing
accumulation of AAV Rep proteins and GFP, respectively.
Together with the data shown in Fig. 5, these data demonstrate
that coinfection with wt AAV2 only modestly affects HSV-1 IE
FIG. 5. Influence of AAV2 coinfection on HSV-1 DNA replica-
tion. Triplicate wells of HeLa cells were mock infected, infected with
HSV-1 (MOI, 1 PFU), coinfected with HSV-1 (MOI, 1 PFU) and wt
AAV2 (MOI, 10, 100, or 1,000 IU), or coinfected with HSV-1 (MOI,
1 PFU) and rAAV2-GFP vector (MOI, 10, 100, or 1,000 TU). At 48 h
p.i., the cells were harvested, and HSV-1 DNA was detected by slot
blotting and hybridization with a probe specific for HSV-1 UL35.
Threefold serial dilutions (do) of HSV-1 replication products in the
absence of AAV infection were used for quantification of HSV-1
replication products in the presence of AAV coinfection. S1 to S3,
sample numbers for triplicate samples; HSV, HSV-1 infected;
wtAAV, coinfected with HSV-1 and wt AAV2; rAAV, coinfected
with HSV-1 and rAAV2-GFP. The numbers in parentheses indicate
the MOIs of AAV2 and rAAV2-GFP in IU and TU, respectively.
TABLE 1. Quantification of HSV-1 DNA replication
products presented in Fig. 5
Infection Relative amt (%) ofHSV-1 DNA
Mock ....................................................................................... 3.7
HSV-1 (input virus)............................................................... 3.7
HSV-1 ..................................................................................... 100
HSV-1  AAV2 (MOI, 10) .................................................100
HSV-1  AAV2 (MOI, 100) ............................................... 60
HSV-1  AAV2 (MOI, 1,000) ............................................ 23
HSV-1  rAAV2-GFP (MOI, 10) ......................................100
HSV-1  rAAV2-GFP (MOI, 100) ....................................100
HSV-1  rAAV2-GFP (MOI, 1,000) .................................100
FIG. 6. Influence of AAV2 coinfection on HSV-1 protein levels.
HeLa cells were mock infected, infected with HSV-1 (MOI, 1 PFU),
coinfected with HSV-1 (MOI, 1 PFU) and increasing amounts of wt
AAV2 (MOI, 10, 100, and 1,000 IU), or coinfected with HSV-1 (MOI,
1 PFU) and increasing amounts of rAAV2-GFP vector (MOI, 10, 100,
and 1,000 TU). At 48 h p.i., the cells were analyzed by SDS-polyacryl-
amide gel electrophoresis and Western blotting with antibodies spe-
cific for (A) HSV-1 ICP4, HSV-1 ICP8, HSV-1 VP16, and HSV-1 gC
or (B) AAV Rep and GFP. Detection of actin served as a loading
control. A sample of HSV-1-infected cells were lysed after 2 h of
absorption, representing the input HSV-1 virus. In panel A, the rela-
tive signal intensities (normalized to that for actin) are indicated as
percentages. The signal intensity of mock-infected cells was set to 0%,
while that of cells infected with HSV-1 alone was set to 100%. M, mock
infected; 2 h, HSV-1 infected and harvested after 2 h of absorption;
wtAAV, wt AAV2 infected; rAAV, rAAV2-GFP infected.
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and early gene expression but markedly inhibits HSV-1 DNA
replication and late gene expression and that AAV2 gene ex-
pression and/or AAV2 DNA replication is responsible for the
effect. However, these results do not specify whether inhibition
of HSV-1 replication is mediated by a function of Rep proteins
or by competition for essential HSV-1 replication factors be-
tween replicating HSV-1 and AAV2 genomes.
Preexisting AAV Rep68/78 proteins inhibit the formation
of mature HSV-1 RCs. In order to test whether the presence of
Rep68/78 proteins is sufficient for the observed inhibition of
HSV-1 replication, we transfected Vero cells with a plasmid
encoding Rep68/78 under the control of the CMV promoter
(pCMVrep68/78_AL) or a control plasmid encoding EGFP in
place of Rep68/78 (pEGFP-N3). The cells were then incubated
for 24 h to allow for the synthesis of Rep proteins before
infection with HSV-1 at an MOI of 10 PFU. Samples of in-
fected cells were fixed at 0, 4, 8, and 12 h p.i. and stained for
HSV-1 ICP8 and AAV Rep proteins. The progression of
HSV-1 infection in rep-expressing cells was analyzed and com-
pared to that in control cells expressing EGFP. Stages of
HSV-1 replication were assessed according to the ICP8 stain-
ing pattern, as previously described (5, 27). As shown in Fig. 7,
the progression from stages I to IV was markedly inhibited in
cells expressing rep. At 12 h p.i., the proportion of cells dis-
playing mature (stage IV) HSV-1 RCs was reduced to 3% in
rep-expressing cells compared to 78% in control cells, while the
proportion of cells in stage I was increased to 31% compared
to 6% in the control cells. Strikingly, 52% of rep-expressing
cells accumulated numerous small nuclear ICP8 foci (Fig. 7A,
panel k). This pattern is reminiscent of the recruitment of ICP8
to sites of cellular DNA synthesis (previously termed “numer-
ous prereplicative sites”), which occurs when cells are infected
in the presence of viral polymerase inhibitors, such as phos-
phonoacetic acid (PAA) or acyclovir, or else when cells are
infected with polymerase-deficient viruses (27, 47). Consistent
with such numerous ICP8 foci being sites of cellular DNA
synthesis, they incorporate BrdU and colocalize with proteins
involved in host cell DNA synthesis (27, 47). We therefore
compared Rep-induced and PAA-induced numerous ICP8 foci
by assessing BrdU incorporation. Vero cells were transfected
with plasmid pCMVrep-ECFP-N3, which encodes a Rep-
ECFP fusion protein under the control of the CMV promoter.
On the following day, the cells were infected with HSV-1 at an
MOI of 10 PFU. As a control, untransfected cells were infected
in the presence of PAA. Pulse labeling with BrdU and staining
with BrdU- and ICP8-specifc antibodies demonstrated that
Rep-induced numerous ICP8 foci are associated with sites of
active DNA synthesis (Fig. 8, panels a to d), similar to PAA-
induced numerous ICP8 foci (Fig. 8, panels e to h). This
finding suggests that Rep-induced numerous ICP8 foci, in
analogy to their PAA-induced counterparts, correspond to
sites of cellular DNA synthesis. Taken together, these data
FIG. 7. Influence of AAV Rep68/78 proteins on HSV-1 RC formation. (A) Vero cells were transfected with plasmid pCMVrep68/78_AL,
encoding Rep68/78 under the control of the CMV promoter, or plasmid pEGFP-N3, containing the same vector backbone and encoding EGFP
instead of Rep68/78. On the following day, the cells were infected with HSV-1 at an MOI of 10 PFU. Cells were fixed at 0, 4, 8, and 12 h p.i. and
stained with anti-ICP8 MAb 7381 and an AF594-conjugated secondary antibody (a to k; red). The cells in panels f to k were also stained with a
rabbit serum specific for Rep and a FITC-conjugated secondary antibody (f to k; green). pEGFP-N3-tranfected cells were identified by EGFP
fluorescence (a to e; green). Cells were observed by epifluorescence microscopy, and stages of HSV-1 replication were assessed according to the
ICP8 staining pattern, as previously described (5, 27). The numbers indicate the proportions of cells in the respective stages at 12 h p.i. and are
means 
 standard deviations for triplicate experiments. (B) Time course of HSV-1 RC formation in transfected cells expressing EGFP or
Rep68/78. The bars show the proportions of cells in the respective stages and represent the mean values for triplicate experiments.
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demonstrate that preexisting Rep68/78 proteins at the time of
infection severely inhibit the formation of HSV-1 RCs and lead
to the accumulation of ICP8 at sites of cellular DNA synthesis.
DISCUSSION
In the present study, we set out to investigate the interaction
between two competing viruses, namely, AAV and its helper
virus HSV-1. In a first set of experiments, we directly assessed
the reciprocal interaction between replicating AAV and HSV-1
DNAs, using live cell visualization assays for rAAV and HSV-1
amplicon replication (Fig. 1). The assays demonstrated the
simultaneous formation of rAAV and HSV-1 amplicon RCs in
a subset of the observed cells. In the majority of cells displaying
mature rAAV RCs, however, mature HSV-1 amplicon RCs
were not detected, indicating inhibition of HSV-1 amplicon
replication in the presence of rAAV DNA and AAV Rep
proteins. Notably, rAAV and HSV-1 amplicon DNAs were
found to replicate in separate RCs, which were often found in
close proximity to each other, possibly reflecting the shared
requirement for HSV-1 replication factors (Fig. 3). AAV and
HSV-1 RCs could be distinguished not only by visualization of
the replicating DNAs but also by their staining patterns for
several viral and cellular proteins. First, the sequence-specific
DNA-binding proteins AAV Rep and HSV-1 ICP4 discrimi-
nated rAAV from HSV-1 RCs. In particular, Rep colocalized
with rAAV DNA but not with HSV-1 amplicon DNA, while
ICP4 accumulated in HSV-1 helper virus RCs but not in rAAV
RCs (Fig. 3 and 4). Second, the ssDNA-binding protein HSV-1
ICP8, although localizing to both rAAV and HSV-1 RCs,
displayed differential staining patterns. Specifically, ICP8 was
found in a punctate staining pattern within HSV-1 RCs, con-
sistent with binding to the single-stranded HSV-1 DNA at the
replication forks but not to the double-stranded HSV-1 repli-
cation products. In contrast, ICP8 showed a more homogenous
distribution within rAAV RCs, reflecting binding to both the
single-stranded AAV DNA at the replication forks and the
single-stranded rAAV replication products (Fig. 4). Third, we
observed hyperphosphorylated replication protein A (RPA) in
rAAV RCs, while hyperphosphorylated RPA did not localize
to productive HSV-1 RCs, indicating the induction of differ-
ential DNA damage responses by AAV and HSV-1 (52;
Strasser et al., unpublished data). Taken together, these ob-
servations demonstrate that AAV and HSV-1 RCs develop as
spatially separate entities accumulating distinct sets of viral
and cellular proteins. This finding is in contradiction with the
assumption that AAV is replicated within HSV-1 RCs, which
was put forward in an earlier report (19). The previous con-
clusion was based on staining patterns of Rep and ICP8 and
likely on the assumed similarity to the situation where Ad acts
as the helper virus. According to our results, however, the
situation with HSV-1 as the helper virus clearly appears to be
different from that described for Ad-aided AAV replication, in
which AAV DNA colocalizes with Ad DNA in early RCs (51).
Nevertheless, in analogy to our results, the maturation of Ad
RCs is significantly inhibited by AAV coinfection or rep over-
expression (51). The mechanisms accounting for these differ-
ences still remain to be determined. It is possible that the
differential influence of components of the cellular DNA re-
pair machinery, for example, the Mre11-Rad50-NBS1 com-
plex, on HSV-1 and Ad replication may be involved in the
processes guiding the formation of AAV, HSV-1, and Ad RCs
(26, 39). However, our findings of the formation of separate
AAV and HSV-1 RCs are consistent with the previously for-
mulated hypothesis that viral RCs are clonal (i.e., derived from
individual parental genomes) and do not merge even after they
have expanded to fill large volumes of the nucleus (10, 16, 38).
In a second set of experiments, we investigated the molec-
ular mechanisms of AAV-mediated inhibition of HSV-1 rep-
lication, as observed with the live covisualization assays. The
analysis of cells coinfected with HSV-1 and either wt AAV2 or
rAAV2-GFP at the levels of HSV-1 DNA (Fig. 5) and HSV-1
proteins (Fig. 6) suggests that AAV-mediated inhibition of
FIG. 8. Rep-induced numerous ICP8 foci are sites of active DNA synthesis. Vero cells were transfected with plasmid pCMVrep-ECFP-N3,
encoding a Rep-ECFP fusion protein (a to d), or left untransfected (e to h). On the following day, the cells were infected with HSV-1 at an MOI
of 10 PFU in the absence (a to d) or presence (e to h) of 400 g/ml PAA. The cells were pulse labeled with 1 mM BrdU for 30 min before fixation
at 12 h p.i. The cells were then stained with the rabbit anti-HSV-1 ICP8 serum 4-83 and a FITC-conjugated secondary antibody as well as with
an anti-BrdU MAb and an AF594-conjugated secondary antibody. Cells were observed by CLSM, with settings specific for ECFP (Rep-ECFP
fusion), FITC (ICP8), and AF594 (BrdU). The images represent projections through three-dimensional reconstructions of the nuclei.
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HSV-1 replication occurs at the level of DNA replication,
while only modestly affecting IE and early gene expression, and
that the effect is dependent on AAV replication and/or rep
expression. In order to dissect whether AAV DNA replication
is required or, alternatively, the Rep proteins per se are suffi-
cient for the inhibition of HSV-1, we analyzed HSV-1 RC
formation in the presence of rep overexpression (Fig. 7). The
assay revealed a pronounced inhibition of HSV-1 RC forma-
tion and the accumulation of ICP8 at sites of cellular DNA
synthesis, a phenomenon previously observed in the presence
of viral polymerase inhibitors (27, 47). Only recently was it
shown that the presence of an inhibited viral polymerase in-
duces the hyperphosphorylation of RPA and its accumulation
at S-phase-specific sites (52). It is possible that Rep induces a
similar response. However, the detailed analysis of viral and
cellular proteins associated with Rep-induced numerous ICP8
foci was postponed to future studies. The findings that (i)
cotransfection of rAAV DNA and AAV rep reduces the fre-
quency of mature HSV-1 amplicon RCs approximately five-
fold, (ii) coinfection of HSV-1-infected cells (MOI, 1 PFU)
with wt AAV2 (MOI, 1,000 IU) reduces the amount of HSV-1
DNA replication products about fourfold (Fig. 5), and (iii)
HSV-1 RCs can coexist with AAV RCs (Fig. 3 and 4) indicate
that AAV-mediated inhibition of HSV-1 replication is far from
being complete. We therefore hypothesize that in the situation
of an AAV–HSV-1 coinfection, the initially low Rep levels
allow a certain degree of HSV-1 replication, and that only the
abundant Rep levels present in a late stage of AAV replication
severely impede the progression of HSV-1 replication. Consis-
tent with this hypothesis, expression of rep from its native
promoters allows for the coexistence of mature AAV and
HSV-1 RCs (Fig. 3 and 4), while the preexpression of
Rep68/78 from the strong CMV promoter almost does not
allow for the formation of mature HSV-1 RCs (Fig. 7). Overall,
our results are consistent with a recent report on the interac-
tion of AAV with Ad (44). It was demonstrated that AAV
coinfection, and in particular the AAV Rep78 protein, mainly
inhibited Ad E4 and late transcription and, to a lesser extent,
E1A and E2A. Interestingly, transfected Rep78 did not reduce
E2A and E4 transcript levels prior to DNA replication, nor did
AAV coinfection affect E2A and E4 mRNA production in the
presence of hydroxyurea. It was concluded that AAV replica-
tion and/or rep gene expression inhibits Ad DNA replication
and that the reduced early gene expression is a consequence
rather than the cause of inhibited DNA replication (44). Al-
though not directly assessed in the present study, it remains
plausible that the moderate decrease in HSV-1 ICP4 and ICP8
protein levels observed in the presence of wt AAV2 was due to
inhibited DNA replication, resulting in reduced levels of tem-
plates for transcription.
The unique requirement for helper virus coinfection might
ensure that AAV only replicates in cells that are no longer
beneficial to the host, thus contributing to the wide distribution
of this otherwise nonpathogenic virus. However, since it is
likely that both AAV and its helper viruses share factors of the
replication machinery, it is plausible that AAV has evolved
mechanisms which limit excessive replication of the helper
virus, e.g., HSV-1. The findings in this report suggest that AAV
has evolved a strategy to inhibit HSV-1 replication without
affecting the synthesis and function of helper virus factors that
are supportive of AAV replication (i.e., the IE gene product
ICP0 and the products of the early genes UL5, UL8, UL52,
and UL29) (14, 50). However, the precise molecular mecha-
nisms underlying this strategy remain to be determined.
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